Updated Jul 16, 2026
Jarrett Jennifer has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $750K.
Jennifer Jarrett is the Chief Operating Officer at Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer treatment. She has also held a similar role at Zura Bio Ltd.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-01 | DMRA | Damora Therapeutics, Inc. | A — Grant or award | 500.0K | $0.00 | |
| 2026-02-06 | SNDX | Syndax Pharmaceuticals Inc | A — Grant or award | 24.0K | $0.00 | |
| 2026-01-27 | RCUS | Arcus Biosciences, Inc. | A — Grant or award | 31.0K | $0.00 | |
| 2025-10-06 | RCUS | Arcus Biosciences, Inc. | S — Open-market sale | 37.8K | $15.05 | $569K |
| 2025-10-06 | RCUS | Arcus Biosciences, Inc. | M — Option exercise | 37.8K | $1.23 | $46K |
| 2025-10-06 | RCUS | Arcus Biosciences, Inc. | S — Open-market sale | 12.5K | $14.54 | $182K |
| 2025-10-06 | RCUS | Arcus Biosciences, Inc. | M — Option exercise | 12.5K | $1.23 | $15K |
| 2024-12-17 | RCUS | Arcus Biosciences, Inc. | F — Tax withholding / forfeiture | 27.5K | $16.08 | $442K |
Jennifer Jarrett is the Chief Operating Officer at Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer treatment. She has also held a similar role at Zura Bio Ltd.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($750K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Jarrett Jennifer profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.